Show summary Hide summary
New research in the American Journal of Ophthalmology raises doubts about the common belief that swapping cigarettes for vapes is a clearly safer option for the eyes. A large Korean cohort study found that people who replaced smoking with smokeless nicotine products showed higher rates of some serious eye conditions than those who stopped using nicotine altogether.
The study, led by researchers at Korea University College of Medicine and based on the Korean National Health Insurance Service database, tracked adults who had smoked in 2011–2012 and reported quitting by 2018–2019. Investigators created a matched sample to compare outcomes for complete quitters versus people who transitioned to noncombustible nicotine products such as e-cigarettes.
Study design and scale
Consumer sentiment improves with cheaper fuel: Americans still doubt economic outlook
Knicks championship crowns Jalen Brunson as a New York sports icon
The analysis began with health records from 179,273 adults. To reduce differences between groups, researchers matched participants on age, sex, underlying health conditions and lifestyle factors, producing a balanced cohort of 32,316 people for direct comparison. Participants were followed for an average of 4.6 years to see who developed major eye diseases.
| Measure | Value |
|---|---|
| Initial pool of adults | 179,273 |
| Matched cohort | 32,316 |
| Average follow-up | 4.6 years |
| Total major eye disease events | 6,328 |
| Rate — complete nicotine quitters | 41.1 per 1,000 person‑years |
| Rate — switched to smokeless products | 44.0 per 1,000 person‑years |
Key findings
Across the follow‑up period, the group that adopted smokeless nicotine alternatives experienced a higher burden of eye disease than those who stopped nicotine entirely.
- The overall risk of major eye disease was about 7% higher for people who switched to smokeless nicotine compared with complete quitters.
- The largest relative increase was for diabetic retinopathy: switching was associated with roughly a 24% greater risk.
- There was also about a 7% higher risk of refractive and accommodation disorders — conditions that impair the eye’s ability to focus.
The numerical difference in incidence rates—41.1 versus 44.0 cases per 1,000 person‑years—translates to a modest but measurable change at the population level when applied across millions of users of nicotine products.
What this means now
For clinicians, public‑health officials and people considering alternatives to smoking, the study suggests that substituting vaping or other noncombustible nicotine products does not eliminate risk to vision and may leave some hazards in place or even increase them.
That matters because vaping rates have risen globally, and many people choose e‑cigarettes as a perceived harm‑reduction strategy. If eye health is part of that risk picture, it should factor into counseling and policy discussions.
Limitations to keep in mind
The authors caution several important caveats:
- The study is observational and retrospective, so it cannot establish a direct causal link between switching and eye disease.
- Exposure data relied on self‑reported questionnaires about smoking and vaping habits, which are vulnerable to misreporting and recall error.
- Unmeasured factors—such as detailed product composition, frequency of use, or changes in health behavior after quitting—could influence outcomes.
In short, the results point to an association rather than definitive proof that vaping causes eye disease. The researchers describe the findings as a reason to reconsider assumptions about the visual safety of noncombustible nicotine products.
Practical takeaways
Readers should view these results as part of a broader evidence base on nicotine and health. Practical considerations from the study include:
- Complete nicotine cessation corresponded with the lowest observed rates of eye disease in this analysis.
- If you use nicotine products and are concerned about vision, periodic eye exams and discussion with a health professional are sensible steps.
- Policymakers and clinicians should weigh potential ocular risks when advising on tobacco harm reduction strategies.
As with any emerging finding, further research—especially prospective studies that track product use in real time and examine biological mechanisms—will be necessary to clarify how different nicotine products affect eye health. Until then, the study offers a fresh perspective on a question that has practical implications for millions of current and former smokers.
